Real-World Validation Study: AI-Based Lung Nodule Malignancy Scoring vs Radiologist Assessment — What Clinicians Need to Know

References

1. 1.AstraZeneca. (2023). Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05817110
2. 2.Gould, M. K., Tang, T., Liu, I. L., Lee, J., Zheng, C., Danforth, K. N., Kosco, A. E., Di Fiore, J. L., & Suh, D. E. (2015). Recent trends in the identification of incidental pulmonary nodules. American Journal of Respiratory and Critical Care Medicine, 192(10), 1208-1214. https://doi.org/10.1164/rccm.201505-0990OC
3. 3.Hammer, M. M., Palazzo, L. L., Kong, C. Y., & Hunsaker, A. R. (2019). Cancer risk in subsolid nodules in the National Lung Screening Trial. Radiology, 293(2), 441-448. https://doi.org/10.1148/radiol.2019182905
4. 4.van Riel, S. J., Sánchez, C. I., Bankier, A. A., Naidich, D. P., Verschakelen, J., Scholten, E. T., Jacobs, C., van Rikxoort, E. M., Peters-Bax, L., Snoeren, M. M., Prokop, M., Schaefer-Prokop, C. M., & van Ginneken, B. (2017). Observer variability for classification of pulmonary nodules on low-dose CT images and its effect on nodule management. Radiology, 283(3), 777-785. https://doi.org/10.1148/radiol.2016151740
5. 5.Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 233-254. https://doi.org/10.3322/caac.21763